---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-018763"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T20:41:50.725185+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q4 2023 net loss $83.5M; cash $750M funds into H2 2026

## Summary
- Net loss $83.5M in Q4 2023 ($0.67 per share) vs $67.5M loss in Q4 2022.
- Full year 2023 net loss $342.0M ($2.79 per share) vs $290.5M in 2022.
- Cash, cash equivalents and investments $750.1M at Dec 31, 2023; expected to fund operations into H2 2026.
- Completed enrollment in RLY-2608 600mg + fulvestrant dose expansion; initiated additional cohorts and triplet with ribociclib.
- Deprioritized further clinical development of RLY-5836.

## SEC filing metadata
- accession: 0000950170-24-018763
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/rlay-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-018763
- JSON: https://secwatch.observer/filing/0000950170-24-018763.json
- Plain text: https://secwatch.observer/filing/0000950170-24-018763.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported the full year 2023 results: revenue Revenue was $25.5 million for the full year 2023, net income Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79, EPS $2.79.
  - Period: the full year 2023
  - Revenue: Revenue was $25.5 million for the full year 2023
  - Net income: Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79
  - EPS: $2.79
  - Result: reported results
  source text: Net loss was $342.0 million for the full year 2023, or a net loss per share of $2.79
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm
- Earnings Releases
  Relay Therapeutics, Inc. reported the fourth quarter of 2023 results: net income Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67, EPS $0.67.
  - Period: the fourth quarter of 2023
  - Net income: Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67
  - EPS: $0.67
  - Result: reported results
  source text: Net loss was $83.5 million for the fourth quarter of 2023, or a net loss per share of $0.67
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017024018763/0000950170-24-018763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.